What is the difference between ARA-290 and Thymosin Alpha-1?

ARA-290 (ARA-290 (Cibinetide)) is graded B and is Not FDA-approved — Phase 2/3 trials for sarcoidosis-associated small fiber neuropathy. Thymosin Alpha-1 (Thymosin Alpha-1 (Tα1)) is graded A and is Approved in 35+ countries for hepatitis B/C, immune support; not FDA-approved in US (orphan-drug designations). They are commonly compared because they share the categories: anti-inflammatory.

Which has stronger clinical evidence — ARA-290 or Thymosin Alpha-1?

On our internal evidence scale, ARA-290 is B and Thymosin Alpha-1 is A. A+ indicates large RCTs plus FDA approval; C indicates primarily preclinical or anecdotal evidence.

What is the typical dose of ARA-290 vs Thymosin Alpha-1?

ARA-290: Trial range: 1–4 mg subcutaneous daily. Thymosin Alpha-1: 1.6 mg twice weekly (subcutaneous). Always work with a licensed clinician — peptide dosing should be individualized.

ARA-290 vs Thymosin Alpha-1

Both ARA-290 and Thymosin Alpha-1 are used for anti-inflammatory. Here's how their evidence, dosing, and regulatory status actually compare.

ARA-290

Evidence B

ARA-290 (Cibinetide)

An 11-amino-acid peptide derived from the helix-B region of erythropoietin. Activates the tissue-protective receptor without erythropoietic side effects. Investigated for neuropathy and inflammation.

View full ARA-290 profile →

Thymosin Alpha-1

Evidence A

Thymosin Alpha-1 (Tα1)

A 28-amino-acid thymic peptide that matures and modulates T-cells. Used internationally as an adjunct in hepatitis, sepsis, and immune-compromised cancer care.

View full Thymosin Alpha-1 profile →

Side-by-Side

Attribute	ARA-290	Thymosin Alpha-1
Evidence Grade	B	A
FDA Status	Not FDA-approved — Phase 2/3 trials for sarcoidosis-associated small fiber neuropathy	Approved in 35+ countries for hepatitis B/C, immune support; not FDA-approved in US (orphan-drug designations)
Typical Dose	Trial range: 1–4 mg subcutaneous daily	1.6 mg twice weekly (subcutaneous)
Clinics Indexed	9	192
Categories	anti-inflammatory, neuroprotection	immune, anti-inflammatory

Key reported benefits — ARA-290

✓Small-fiber neuropathy improvement
✓Anti-inflammatory
✓No erythrocytosis

Key reported benefits — Thymosin Alpha-1

✓T-cell maturation
✓Antiviral immunity
✓Tumor immune support
✓Sepsis adjunct

Educational use only

This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.

← Back to all comparisons